Get the Stockscreener App
57.65
1.49%
-0.87
Pre-market:
57.55
-0.10
-0.17%
Royalty Pharma Plc stock is traded at $57.65, with a volume of 2.80M.
It is down -1.49% in the last 24 hours and down -5.97% over the past month.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
See More
Previous Close:
$58.52
Open:
$58.52
24h Volume:
2.80M
Relative Volume:
0.92
Market Cap:
$25.67B
Revenue:
$2.44B
Net Income/Loss:
$1.36B
P/E Ratio:
30.19
EPS:
1.9093
Net Cash Flow:
$574.14M
1W Performance:
-1.40%
1M Performance:
-5.97%
6M Performance:
+26.40%
1Y Performance:
+59.08%
1-Day Range:
$57.63
$59.02
1-Week Range:
$57.63
$59.18
52-Week Range:
$34.63
$64.38
Royalty Pharma Plc Stock (RPRX) Company Profile
Name
Royalty Pharma Plc
Sector
Industry
Phone
(212) 883-0200
Address
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX vs VRTX, REGN, MRNA, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
57.65 | 25.67B | 2.44B | 1.36B | 574.14M | 1.9093 |
VRTX
Vertex Pharmaceuticals Inc
|
516.34 | 130.87B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
801.82 | 82.55B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
182.11 | 72.70B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
945.82 | 59.17B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
365.00 | 41.29B | 5.76B | 514.49M | 1.10B | 4.4813 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Upgrade | UBS | Neutral → Buy |
| Sep-30-25 | Initiated | Goldman | Buy |
| May-16-25 | Initiated | Morgan Stanley | Overweight |
| Jun-03-24 | Downgrade | UBS | Buy → Neutral |
| Jun-14-22 | Resumed | UBS | Buy |
| May-13-22 | Initiated | Scotiabank | Sector Outperform |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-14-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Oct-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Jul-30-21 | Initiated | Tigress Financial | Buy |
| Nov-09-20 | Upgrade | UBS | Neutral → Buy |
| Jul-14-20 | Initiated | Evercore ISI | In-line |
| Jul-13-20 | Initiated | BofA Securities | Buy |
| Jul-13-20 | Initiated | Citigroup | Neutral |
| Jul-13-20 | Initiated | Cowen | Outperform |
| Jul-13-20 | Initiated | Goldman | Neutral |
| Jul-13-20 | Initiated | JP Morgan | Neutral |
| Jul-13-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-13-20 | Initiated | SunTrust | Buy |
| Jul-13-20 | Initiated | UBS | Neutral |
View All
Royalty Pharma Plc Stock (RPRX) Latest News
Royalty Pharma PLC (RPD) Q4 2022 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPD) Q2 2023 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPD) Q3 2023 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPD) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPD) Q1 2026 Earnings ReportResults, Call & Slides - TipRanks
RPRX: Strategic AI, scalable deal models, and China expansion drive robust, diversified growth - TradingView
Royalty Pharma PLC (RPD) Q2 2024 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPD) Q4 2024 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPD) Q2 2026 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma plc (RPRX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Royalty Pharma plc (RPRX) stock price, news, quote and history - Yahoo Finance Singapore
Royalty Pharma at Bank of America Global Healthcare Conference: growth even with policy risks - Investing.com Nigeria
Royalty Pharma (RPRX) Stock Looks Richly Priced After Its 136% Run - Yahoo Finance
Price-Driven Insight from (RPRX) for Rule-Based Strategy - Stock Traders Daily
Royalty Pharma (RPRX) Could Be 10% Undervalued As Conference Spotlight Returns - Yahoo Finance
Royalty Pharma PLC (RPD) Q1 2025 Earnings ReportResults, Call & Slides - TipRanks
Andra AP fonden Lowers Stock Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC (RPD) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPD) Q4 2025 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma (RPRX) holder plans new sale after selling 350,000 shares - Stock Titan
Royalty Pharma PLC (RPD) Q4 2023 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma plc (RPRX) Stock Analysis: Exploring a 11.5% Potential Upside in the Biotech Royalty Space - DirectorsTalk Interviews
NewEdge Advisors LLC Raises Stock Position in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC $RPRX Shares Sold by Corient Private Wealth LP - MarketBeat
Could Royalty Pharma’s (NASDAQ:RPRX) Story Be Changing Fast? - kalkinemedia.com
Royalty Pharma PLC (NASDAQ:RPRX) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Is Royalty Pharma (RPRX) Below Fair Value After The Pelacarsen Trial Miss? - simplywall.st
A $7.5 million gift will help develop new blood cancer treatments - Stock Titan
California State Teachers Retirement System Decreases Stake in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma at Morgan Stanley conference: growth broadens beyond royalties By Investing.com - Investing.com UK
WINTON GROUP Ltd Invests $1.28 Million in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC $RPRX Shares Sold by National Pension Service - MarketBeat
Tidal Investments LLC Has $6.63 Million Holdings in Royalty Pharma PLC $RPRX - MarketBeat
(RPRX) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Wall Street Zen Upgrades Royalty Pharma (NASDAQ:RPRX) to Strong-Buy - MarketBeat
Engineers Gate Manager LP Grows Position in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma (RPRX): Can Downside Protection Offset Pelacarsen’s Phase 3 Failure? - Yahoo Finance
Squarepoint Ops LLC Decreases Stock Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma to present at Morgan Stanley global healthcare investor conference - Bitget
Royalty Pharma to present at upcoming investor conferences - marketscreener.com
Royalty Pharma to Present at Upcoming Investor Conferences - Moomoo
Royalty Pharma PLC $RPRX Shares Sold by C WorldWide Group Holding A S - MarketBeat
If You Invested $1000 In Royalty Pharma Stock 15 Years Ago, You Would Have This Much Today - Benzinga
TD Cowen raises Royalty Pharma stock price target on unchanged growth outlook - Investing.com Nigeria
TD Cowen raises Royalty Pharma stock price target on unchanged growth outlook By Investing.com - Investing.com South Africa
Royalty Pharma (NASDAQ:RPRX) Shares Gap DownWhat's Next? - MarketBeat
RPRX Maintained by TD Cowen -- Price Target Raised to $68.00 - GuruFocus
Royalty Pharma (RPRX) PT Raised to $68 at TD Cowen - StreetInsider
TD Cowen Issues Positive Forecast for Royalty Pharma (NASDAQ:RPRX) Stock Price - MarketBeat
Why Is Novartis Stock Falling Today?Novartis (NYSE:NVS), Ionis Pharmaceuticals (NASDAQ:IONS), Royalty - Benzinga
Royalty Pharma PLC (RPRX) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma Plc Stock (RPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Royalty Pharma Plc Stock (RPRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hite Christopher | EVP & Chairman, Partnering |
Aug 18 '26 |
Sale |
59.97 |
100,000 |
5,997,250 |
370,401 |
2.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):